Vapotherm INC: insider trades · United States · SEC (Form 4)

About Vapotherm INC

Vapotherm Inc. is a U.S.-based medical device company listed on the American market NYSE/NASDAQ and headquartered in Exeter, New Hampshire, United States. The company focuses on advanced respiratory support technologies, with a core positioning around patient comfort and non-invasive treatment for acute and chronic breathing disorders. Founded in 1993 and later reincorporated in Delaware in 2013, Vapotherm built its franchise as a niche respiratory-therapy specialist rather than a broad multi-platform medtech group. From an operating standpoint, Vapotherm’s business centers on high-velocity therapy systems, related consumables, and accessories, along with adjacent respiratory-support solutions. Its products are primarily used in hospitals, emergency departments, intensive care settings, and other acute-care environments where ease of use, rapid deployment, and patient tolerance matter. The company’s portfolio includes its next-generation HVT platform and associated device ecosystem designed to support clinicians treating patients with respiratory distress while offering an alternative to more invasive forms of ventilation. Competitively, Vapotherm is best viewed as a specialized player. Its differentiation comes from product focus, clinical workflow integration, and adoption within acute-care institutions, rather than from scale or breadth of portfolio. That niche positioning can be attractive in segments where hospitals want non-invasive respiratory options and differentiated therapy outcomes, but it also means the company is sensitive to hospital purchasing cycles, reimbursement dynamics, regulatory execution, and the pace of commercial adoption. In this sense, Vapotherm’s market position is more about targeted clinical utility than mass-market volume. Geographically, the company is anchored in the United States, with its principal executive offices in Exeter, New Hampshire, and it has also referenced a U.K. reporting unit in its SEC filings. This suggests a commercial footprint that extends beyond the U.S., although the domestic market remains its main reference point. Recent developments have been important. In December 2025, Vapotherm announced a strategic partnership with Flight Medical Innovations to bring the VentO2ux ventilator to U.S. hospitals, broadening its portfolio beyond high-velocity therapy devices into a more complete respiratory-support offering. In 2024, Vapotherm also pursued a strategic transaction that resulted in acquisition by an affiliate-linked vehicle associated with Perceptive Advisors, a major corporate event that remains highly relevant for investors assessing the company’s equity story and future operating profile.